Synthesis, Inhibition Potency, Binding Mode, and Antiprotozoal Activities of Fluorescent Inhibitors of Trypanothione Reductase Based on Mepacrine‐Conjugated Diaryl Sulfide Scaffolds

Trypanothione reductase (TR) is a flavoenzyme unique to trypanosomatid parasites and a target for lead discovery programs. Various inhibitor scaffolds have emerged in the past, exhibiting moderate affinity for the parasite enzyme. Herein we show that the combination of two structural motifs of known TR inhibitors — diaryl sulfides and mepacrine — enables the simultaneous addressing of two hydrophobic patches in the active site. The binding efficacy of these conjugates is enhanced over that of the respective parent inhibitors. They show Kic values for the parasite enzyme down to 0.9±0.1 μm and exhibit high selectivity for TR over human glutathione reductase (GR). Despite their considerable molecular mass and in some cases permanent positive charges, in vitro studies revealed IC50 values in the low micromolar to sub‐micromolar range against Trypanosoma brucei rhodesiense and Trypanosoma cruzi, as well as the malaria parasite Plasmodium falciparum, which lack trypanothione metabolism. The inhibitors exhibit strong fluorescence due to their aminoacridine moiety. This feature allows visualization of the drugs in the parasite where high accumulation was observed by fluorescence microscopy even after short exposure times.

[1]  Isabelle R. E. Nett,et al.  Improved Tricyclic Inhibitors of Trypanothione Reductase by Screening and Chemical Synthesis , 2009, ChemMedChem.

[2]  I. Gilbert,et al.  Synthesis and Evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase , 2009, ChemMedChem.

[3]  F. Diederich,et al.  Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiprotozoal activities. , 2008, Organic & biomolecular chemistry.

[4]  F. Diederich,et al.  Betraying the Parasite’s Redox System: Diaryl Sulfide‐Based Inhibitors of Trypanothione Reductase: Subversive Substrates and Antitrypanosomal Properties , 2007, ChemMedChem.

[5]  I. Gilbert,et al.  Target assessment for antiparasitic drug discovery. , 2007, Trends in parasitology.

[6]  W. Hunter Picking pockets to fuel antimicrobial drug discovery. , 2007, Biochemical Society transactions.

[7]  O. Tapia,et al.  Interaction energies of nitrofurans with trypanothione reductase and glutathione reductase studied by molecular docking , 2007 .

[8]  J. Alvar,et al.  Leishmaniasis and poverty. , 2006, Trends in parasitology.

[9]  D. Boykin,et al.  Accumulation and Intracellular Distribution of Antitrypanosomal Diamidine Compounds DB75 and DB820 in African Trypanosomes , 2006, Antimicrobial Agents and Chemotherapy.

[10]  V. Yardley,et al.  Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. , 2005, Journal of medicinal chemistry.

[11]  R. L. Krauth-Siegel,et al.  Dithiolproteine als Hüter des intrazellulären Redoxmilieus bei Parasiten: alte und neue Wirkstoff‐Targets bei Trypanosomiasis und Malaria , 2005 .

[12]  R. Schirmer,et al.  Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. , 2005, Angewandte Chemie.

[13]  R. Krauth-Siegel,et al.  Parasite-specific trypanothione reductase as a drug target molecule , 2003, Parasitology Research.

[14]  Wim G J Hol,et al.  Drugs to Combat Tropical Protozoan Parasites , 2002, Science.

[15]  H. D. Koning Transporters in African trypanosomes: role in drug action and resistance. , 2001 .

[16]  J. Keiser,et al.  New drugs for the treatment of human African trypanosomiasis: research and development. , 2001, Trends in parasitology.

[17]  D. Marks,et al.  Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines , 2000 .

[18]  T. Nevalainen,et al.  Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery. , 2000, Journal of medicinal chemistry.

[19]  H. Tanowitz,et al.  African trypanosomiasis (sleeping sickness). , 2000 .

[20]  R. Krauth-Siegel,et al.  Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships. , 1999, Journal of medicinal chemistry.

[21]  A. Orjales,et al.  2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives. , 1999, Journal of medicinal chemistry.

[22]  M. Berriman,et al.  Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. , 1999, Structure.

[23]  Ken Blanchard,et al.  Mission Possible , 1999 .

[24]  A. Fairlamb,et al.  Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. , 1998, Journal of medicinal chemistry.

[25]  E. Davioud‐Charvet,et al.  New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase. , 1997, Bioorganic & medicinal chemistry.

[26]  C. Sergheraert,et al.  2-Amino diphenylsulfides as inhibitors of trypanothione reductase: modification of the side chain. , 1996, Bioorganic & medicinal chemistry.

[27]  W. Kabsch,et al.  Crystal structure of the Trypanosoma cruzi trypanothione reductase·mepacrine complex , 1996, Proteins.

[28]  C. Sergheraert,et al.  2-Amino diphenylsulfides as new inhibitors of trypanothione reductase. , 1995, International journal of antimicrobial agents.

[29]  A. Fairlamb,et al.  Uptake of Diamidine Drugs by the P2 Nucleoside Transporter in Melarsen-sensitive and -resistant Trypanosoma brucei brucei(*) , 1995, The Journal of Biological Chemistry.

[30]  Paul R. Gerber,et al.  MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..

[31]  J. Blanchard,et al.  Mechanism of reduction of quinones by Trypanosoma congolense trypanothione reductase. , 1994, Biochemistry.

[32]  A. Fairlamb,et al.  Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. , 1992, The Biochemical journal.

[33]  A. Fairlamb,et al.  "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Chait,et al.  Trypanothione: a novel bis(glutathionyl)spermidine cofactor for glutathione reductase in trypanosomatids. , 1985, Science.

[35]  J. Wilshire,et al.  The preparation of some 2-nitroacridines and related compounds , 1981 .